Short Interest in Celularity Inc. (NASDAQ:CELUW) Declines By 60.1%
Short Interest in Celularity Inc. (NASDAQ:CELUW) Declines By 60.1%
Celularity Inc. (NASDAQ:CELUW – Get Rating) was the recipient of a significant decline in short interest in the month of February. As of February 28th, there was short interest totalling 7,300 shares, a decline of 60.1% from the February 13th total of 18,300 shares. Based on an average daily trading volume, of 14,600 shares, the short-interest ratio is currently 0.5 days.
Celularity Inc.（纳斯达克股票代码：CELUW — Get Rating）是2月份空头利率大幅下降的受益者。截至2月28日，空头利率共计7,300股，较2月13日的18,300股下降了60.1％。根据14,600股的平均每日交易量，空头利率目前为0.5天。
Celularity Trading Up 14.3 %
Celularity 交易上涨了 14.3%
NASDAQ:CELUW traded up $0.01 during trading hours on Friday, hitting $0.08. 82,509 shares of the company's stock traded hands, compared to its average volume of 17,187. Celularity has a twelve month low of $0.06 and a twelve month high of $1.99. The stock has a fifty day moving average price of $0.09.
纳斯达克股票代码：CELUW在周五交易时段上涨0.01美元，至0.08美元。该公司股票交易量为82,509股，而平均交易量为17,187股。Celularity创下十二个月低点0.06美元，十二个月高点1.99美元。该股的五十天移动平均价格为0.09美元。
Celularity Company Profile
Celularity 公司简介
(Get Rating)
（获取评级）
Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy.
Celularity Inc是一家临床阶段的生物技术公司，开发现成的胎盘衍生异体细胞疗法，用于治疗癌症、免疫和传染病。它通过三个部分运作：细胞疗法、退行性疾病和生物银行。该公司的主要治疗项目包括 CYCART-19，一种胎盘衍生的 CAR-T 疗法，目前处于治疗 B 细胞恶性肿瘤的 I 期临床试验中；CYNK-001，胎盘衍生的未修饰自然杀伤细胞 (NK) 细胞，正在进行治疗急性髓系白血病的 I 期临床试验，以及治疗多形性胶质母细胞瘤和 COVID-19 的 I 期临床试验；CYNK-101 转基因 NK 细胞，正在进行治疗 HER2+ 胃癌和胃食管癌的 I 期临床试验；APPL-001，胎盘-衍生的间充质样粘附基质细胞，处于治疗克罗恩病的临床前阶段；以及 PDA-002，一种胎盘衍生的间充质样粘附基质细胞，处于治疗面部肩胛肌营养不良症的临床前阶段。
Featured Stories
精选故事
- Get a free copy of the StockNews.com research report on Celularity (CELUW)
- What the SVB Financial Collapse Means for U.S. Banks
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- 免费获取 StockNews.com 关于 Celularity (CELUW) 的研究报告
- SVB 金融崩溃对美国银行意味着什么
- MarketBeat 一周回顾 — 3/6 — 3/10
- 2 只海上钻探股票将获得丰厚利润
- 三只主打股有两位数的上涨空间
- 投资者能否信任消费者提升美国户外品牌？
Receive News & Ratings for Celularity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celularity and related companies with MarketBeat.com's FREE daily email newsletter.
接收 Celularity Daily 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Celularity及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。